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OBJECTIVES This study was designed to evaluate left ventricular (LV) anatomy and function in patients
with Cushing’s syndrome.
BACKGROUND A high prevalence of LV hypertrophy and concentric remodeling has been reported in
Cushing’s syndrome, although no data have been reported on LV systolic and diastolic
function.
METHODS Forty-two consecutive patients with Cushing’s syndrome and 42 control subjects, matched for
age, gender, and blood pressure, were studied. Left ventricular mass index (LVMI) and
relative wall thickness (RWT) were measured by echocardiography, endocardial and midwall
fractional shortening (FS) were assessed, and diastolic filling was measured by Doppler
transmitral flow.
RESULTS The RWT was significantly greater in Cushing patients than in controls. Left ventricular
hypertrophy and concentric remodeling were observed in 10 and 26 patients with Cushing’s
syndrome, respectively. In Cushing patients, midwall FS was significantly reduced compared
with controls (16.2  3% vs. 21  4.5%, p  0.01). The ratio of transmitral E and A flow
velocities was reduced and E deceleration time was prolonged in Cushing patients compared
with controls (p  0.03 and p  0.001, respectively).
CONCLUSIONS In patients with Cushing’s syndrome, cardiac structural changes are associated with reduced
midwall systolic performance and with diastolic dysfunction that may contribute to the high
risk of cardiovascular events observed in these patients. (J Am Coll Cardiol 2003;41:
2275–9) © 2003 by the American College of Cardiology Foundation
Cardiovascular complications of Cushing’s syndrome cause
a mortality rate that is fourfold higher than that expected in
the normal population (1). Cortisol hypersecretion causes
central obesity, hypertension, impairment of glucose toler-
ance or diabetes, hyperlipidemia, and a pro-thrombotic
state. Altogether, these abnormalities contribute to the high
cardiovascular risks, such as myocardial infarction and
stroke, associated with this disease (2,3). We previously
documented in Cushing’s syndrome a characteristic alter-
ation of cardiac structure, that is, a high relative wall
thickness (RWT), which was not related to blood pressure
(BP) levels (4). We therefore indicated the exposure to
increased cortisol per se as the determinant of left ventric-
ular (LV) concentric remodeling, proposing that this feature
may contribute to high cardiovascular morbidity (2,3,5).
The aim of this study was to further investigate, in a larger
group of patients with Cushing’s syndrome, LV structural
and functional characteristics. For this purpose, we evalu-
ated LV systolic performance by the measurement of
endocardial and midwall fractional shortening (FS) and
diastolic filling by pulsed Doppler echocardiography. In
fact, midwall systolic dysfunction seems a more reliable
measure of myocardial contractility and may represent a
predictor of an adverse outcome in arterial hypertension
(6,7). Very recently, diastolic filling abnormalities have also
been shown to influence the occurrence of heart failure and
cardiovascular events (8–10).
METHODS
Study population. We studied 42 consecutive patients with
newly diagnosed Cushing’s syndrome. The diagnosis of Cush-
ing’s syndrome was based on standard criteria and proved at
surgery in all cases (1); 24-h urinary cortisol values were
1.522  1.044 nmol/day. Among patients with Cushing’s
syndrome, 36 had pituitary-dependent bilateral adrenal hyper-
plasia, one had ectopic adrenocorticotrophic hormone produc-
tion, six had an adrenal adenoma, and one had an adrenal
carcinoma. Duration of disease (ranging from 2 to 50 months)
was obtained from careful investigation of the patient’s history,
including early symptoms. In 32 patients with Cushing’s
syndrome, onset of hypertension was coincidental with the
appearance of other clinical features and BP values at diagnosis
were 156  22/97  11 mm Hg, whereas in 10 patients BP
values were always within normal limits. Five patients (three
hypertensive and two normotensive) with Cushing’s syndrome
had diabetes mellitus well controlled by oral hypoglycemic
agents at the time of the study.
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Patients with Cushing’s disease were compared with 42
control cases, purposely matched for gender, age, body mass
index, smoking habit, lipid levels, BP levels, and duration of
hypertension. Controls were selected among hypertensive
patients seen at our outpatient clinic and from a general
population cohort under evaluation for cardiovascular risk
stratification (11).
In 21 of 32 hypertensive patients with Cushing’s syn-
drome, despite a combination of at least two antihyperten-
sive drugs (including diuretics and/or calcium antagonists
and/or angiotensin-converting enzyme inhibitors and/or
angiotensin II receptor antagonists), BP response to therapy
was unsatisfactory (i.e., supine diastolic BP 90 mm Hg),
in agreement with previous findings (12). For this reason we
included in the group of control cases 21 patients previously
treated with at least two drugs, matched for BP values, and
11 never-treated hypertensive patients; these patients were
selected after extensive hormonal and instrumental workup
for the exclusion of secondary hypertension and other
diseases (ischemic heart disease, heart or renal failure,
valvular disease, and/or thyroid hyper- or hypofunction)
(13). All patients and controls underwent the echocardio-
graphic examination after a short period (10 to 15 days) of
antihypertensive treatment withdrawal. Mean values of age,
body mass index, systolic and diastolic BP, and duration of
hypertension of the two groups of subjects are reported in
Table 1. The local ethics committees approved the study.
Echocardiographic examination. Echocardiography was
performed by standardized procedures with two Sonos 1500
echo machines (Agilent Technologies). The echocardio-
graphic study protocol recorded at least 10 cycles of two-
dimensional parasternal long- and short-axis LV views with
optimal orientation of the M-mode cursor beam.
The LV internal dimensions, interventricular septum,
and posterior wall thickness were measured according to the
recommendations of the American Society of Echocardiog-
raphy (14). End-diastolic RWT (i.e., the ratio of posterior
wall thickness to one-half LV internal dimension) was
calculated as index of LV geometric pattern; values higher
than 0.44 were considered to indicate LV concentric geom-
etry (15). The Penn Convention was used to calculate LV
mass by an anatomically validated formula (16); LV mass
was indexed by body height to the 2.7 power, and the
partition value of 51 g/m2.7 was used to define LV hyper-
trophy in both genders (17).
Left ventricular systolic function was estimated by both
endocardial FS and midwall FS, as previously reported
(7,18). Endocardial FS was defined as [(LVDd  LVDs)/
LVDd]  100. Midwall FS was calculated by taking into
account epicardial migration of the midwall during systole
according to the following formula:
Midwall FS
LVDd PWTd/2 IVSTd/2 LVDs hs/2
LVDd PWTd/2 IVSTd/2
where LVD  left ventricular diameter, PWT  posterior
wall thickness, IVST  interventricular septum thickness,
h  combined thickness of interventricular septum and
posterior wall, s  end-systole, and d  end-diastole.
Myocardial contractile efficiency is usually examined by
the relation of systolic shortening to end-systolic stress
(ESS). In order to identify deviations from normal in
contractile performance, endocardial FS was also expressed
as a percentage of the value predicted for meridional ESS on
findings in normal subjects (18). Meridional ESS was
calculated by the standard method of Reicheck et al. (19).
Accordingly, midwall shortening was related to circumfer-
ential ESS, calculated at the midwall by the method of
Gaasch et al. (20). Observed midwall FS was expressed as a
percent of the value predicted from circumferential ESS
with an equation derived from normal adults (18).
In 22 patients (17 hypertensive and 5 normotensive) with
Cushing’s syndrome and in 22 matched controls, pulsed
Doppler recordings at the level of the mitral valve tips from
apical four-chamber two-dimensional views were obtained
in order to measure early (E) and late (A) wave diastolic
filling velocities, their ratio (E/A ratio), and E-wave decel-
eration time (18,21).
Two different readers, unaware of the patients’ or con-
trols’ identity, performed all echocardiographic and Doppler
measurements.
All the echocardiographic and Doppler parameters were
selected before the initiation of the investigation, in order to
evaluate abnormalities of LV structure by LV mass and
geometry, of systolic performance by endocardial and mid-
wall FS, and of diastolic filling by the E/A ratio and E-wave
deceleration. All these parameters’ abnormalities are known
to occur in arterial hypertension and may influence clinical
outcome (4–10,18).
Abbreviations and Acronyms
BP  blood pressure
ESS  end-systolic stress
FS  fractional shortening
LV  left ventricle/ventricular
LVMI  left ventricular mass index
RWT  relative wall thickness
Table 1. Demographic Characteristics of Cushing Patients and
Controls
Cushing
Patients Controls p
Age (yrs) 39  12 40.5  11 NS
Gender (F/M) 30/12 30/12 NS
Body mass index (kg/m2) 28  4.8 28  4.0 NS
Hypertensive/normotensive patients 32/10 32/10 NS
Duration of hypertension, months 10.8  14 11.8  11 NS
Systolic BP (mm Hg) 153  21 151  19 NS
Diastolic BP (mm Hg) 96  13 95  12 NS
Total cholesterol (mmol/l) 6.01  0.82 5.5  0.98 NS
Fasting glucose (mmol/l) 5.7  1.07 5.45  1.1 NS
BP  blood pressure.
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Hormone measurement. Twenty-four-hour urinary corti-
sol was measured by radioimmunoassay using a kit from
Diagnostic Products Co. (Los Angeles, California). The
intra-assay coefficient of variation was 6%, and the inter-
assay coefficient of variation was 8.2%. The normal range
was 55 to 330 nmol/day.
Statistical analysis. The statistical significance of differ-
ences between the two groups (Cushing patients and con-
trols) was assessed by unpaired t-test, with Bonferroni correc-
tion for multiple comparisons. Chi-square statistic was used to
assess differences of categorical variables between groups.
Relationships between echocardiographic indices (LVMI,
RWT, E/A ratio, E-wave deceleration, midwall FS) and
urinary cortisol or duration of disease were investigated
calculating the rank order Spearman’s coefficient. Multivar-
iate analysis was performed to assess the independent effect
of hypertension and presence or absence of Cushing’s
syndrome diagnosis on RWT, midwall FS, E/A ratio, and
E-wave deceleration time. All statistical tests were two-
tailed at the p value of 0.05. Results are expressed as mean
 SD. All analyses were carried out with the SPSS 10.01
statistical package.
RESULTS
LV structure. The echocardiographic parameters of pa-
tients with Cushing’s syndrome and matched controls are
reported in Table 2. No difference in heart rate or in atrial
size was found between patients and controls.
End-diastolic diameter was significantly lower in Cush-
ing patients, suggesting the absence of volume overload in
these patients. Left ventricular mass index and RWT were
significantly higher in Cushing patients than in controls.
Left ventricular hypertrophy was observed in 10 of 42
Cushing patients and in 3 of 42 controls; concentric
remodeling was observed in 26 of 42 Cushing patients and
in none of the controls.
Among patients with Cushing’s syndrome, LVMI was 42
 12 g/m2.7 and 38  14 g/m2.7, and RWT was 0.47 
0.10 and 0.40  0.09 in the 32 hypertensives and in the 10
normotensives, respectively.
Left ventricular mass index was independently associated
with hypertension (F  7.12, p  0.006) and Cushing’s
syndrome (F 6.59, p 0.012). Left ventricular RWT was
also independently associated with hypertension (F  14.2,
p  0.001) and Cushing’s syndrome (F  49.2, p  0.001).
In patients with Cushing’s syndrome, RWT but not
LVMI was related with the duration of disease (r  0.32,
p  0.05) but not with urinary cortisol levels.
LV systolic function. No significant differences between
Cushing patients and controls were observed for endocardial
FS, whereas stress-adjusted endocardial FS was significantly
lower in Cushing patients than in controls (Table 3).
In Cushing patients, midwall FS (absolute and stress-
adjusted values) was significantly reduced compared with
controls (Table 3), with no significant difference between
hypertensives and normotensives (18  3 vs. 16  3, p 
0.62). Midwall FS was independently associated with Cush-
ing’s syndrome (F  22.6, p  0.001) and with hyperten-
sion (F  5.78, p  0.012).
LV diastolic function. The ratio of E/A velocities was
reduced and the E-wave deceleration was prolonged in
Cushing patients compared with controls (Table 3). The
E/A ratio was independently associated with hypertension
(F  17.3, p  0.001) and Cushing’s syndrome (F  12.9,
p  0.001), whereas the duration of E-wave deceleration
was independently associated with Cushing’s syndrome (F
 23.3, p  0.001) but not with hypertension (F 1.93, p
 0.18).
In patients with Cushing’s syndrome, the E/A ratio (r 
0.39, p  0.01) and the E-wave deceleration time (r 
0.31, p  0.05) were significantly related with the duration
of the disease. No correlation was observed between the
urinary cortisol levels and Doppler parameters of diastolic
filling.
DISCUSSION
This study has demonstrated for the first time that in
patients with Cushing’s syndrome the abnormalities of LV
anatomy are associated with important functional conse-
Table 2. Echocardiographic Features of Cushing Patients and
Controls
Cushing
Patients Controls p
Left atrium diameter (mm) 32  5.6 34  5.4 0.14
LVDd (mm) 43.7  4.0 49.5  4.1  0.001
LVDs (mm) 26.5  4.2 31  4.6  0.001
LV IVSd (mm) 10.1  2.2 8.8  1.3 0.05
LV PWd (mm) 9.8  1.71 7.8  1.15 0.005
RWT 0.46  0.1 0.32  0.05 0.008
LV mass (g) 155.4  47 145  39 0.18
LV mass index (g/m2.7) 41  12.7 34.8  8 0.021
LV  left ventricular; LVDd  left ventricular end-diastolic diameter; LVDs  left
ventricular end-systolic diameter; LV IVSd  left ventricular interventricular septum
diameter; LV PWd  left ventricular posterior wall diameter.
Table 3. Systolic Performance and Diastolic Filling Parameters
Cushing
Patients Controls p
Endocardial FS (%) 39  7.6 39  7.5 0.88
Predicted endocardial FS,
% (mESS adjusted)
39  3.8 35.4  2.3
Endocardial FS (% of
predicted value)
99.6  14 110  18 0.001
Midwall FS (%) 16.2  3 20.5  4.5  0.01
Predicted midwall FS (%)
(cESS adjusted)
17.9  0.6 17.6  0.7
Midwall FS (% of
predicted value)
89  17 115  15  0.0001
Ejection fraction (%) 75  6 74  10 0.12
E velocity (cm/s) 55.6  12 78  21 0.005
A velocity (cm/s) 62  13 65  22 0.21
E/A ratio 0.94  0.27 1.18  0.32 0.03
E-wave deceleration time (ms) 205  36 150  30  0.001
ESS  end-systolic shortening; FS  fractional shortening.
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quences: a decrease of LV systolic performance measured at
the midwall and a change of diastolic filling toward abnor-
mal relaxation pattern.
In addition, our results expand previous data (4), con-
firming a significantly higher frequency of concentric remod-
eling (normal LV mass and concentric geometry) in patients
with Cushing’s syndrome than in controls, accurately matched
not only for demographic characteristics but also for BP values,
previous antihypertensive treatment type, and duration.
The use of echocardiographic determination of midwall
LV performance is considered a more appropriate method
of evaluating ventricular systolic function (6,7), because the
inward movement by the thickened inner layer of a hyper-
trophic ventricle is greater than the movement of the inner
layer of a normal ventricle. Therefore, it has been possible to
identify a subgroup of asymptomatic hypertensive patients
who exhibit hemodynamic characteristics associated with an
increased cardiovascular risk (15,22–27) and a reduction of
LV myocardial performance at rest (25–27). The presence
of depressed midwall shortening is a predictor of an adverse
outcome in arterial hypertension (6,7), and the combination
of higher LV mass and lower midwall shortening identifies
patients with a marked increase of risk (6).
The impact of diastolic dysfunction on cardiac morbidity
and mortality is becoming increasingly understood (8–
10,28,29), and diastolic filling abnormalities may be iden-
tified by the use of non-invasive, simple and repeatable
Doppler transmitral flow velocities measurements (28).
In Cushing’s syndrome, the frequency of concentric
remodeling and of diastolic dysfunction parameters in-
creased with the duration of disease and was not related to
cortisol levels. This suggests that a long-lasting exposure to
high cortisol levels might be more relevant than the mag-
nitude of hormone levels. Duration of disease has been also
seen as the determinant of persistent high BP levels after
successful surgery in hypertensive patients with Cushing’s
syndrome (30).
Obesity has been associated per se with abnormalities of
both midwall systolic performance and diastolic filling,
possibly influencing, at least in part, our findings (31).
However, truncular fat distribution in Cushing patients is
different from traditional obesity, and the appropriateness of
body mass index correction for obese patients with Cush-
ing’s disease is unknown.
The mechanism(s) by which cortisol may determine an
increase in LV wall thickness in our patients is not clear.
The rise in BP seems not to be essential for the development
of initial structural changes in LV wall, because an increase
in RWT was demonstrated in normotensive patients com-
pared with controls. Cardiac structure may be influenced by
endocrine abnormalities through hemodynamic changes,
and in Cushing patients a volume overload would have been
expected. At variance, we have observed a smaller cavity size
of the LV, suggesting the absence of an increase in preload.
Because all echocardiographic studies were performed a
short time after withdrawal from treatment in previously
treated patients, the possible influence of antihypertensive
drugs on LV dimensions (such a decrease in LV cavity size and
a concomitant increase in RWT) can be reasonably ruled out.
Cortisol is thought to have a range of effects on cardio-
vascular regulation (5). In addition to inducing hypertension
by a number of mechanisms, cortisol may act directly on
myocardial tissue. Indeed, glucocorticoid receptors have
been shown in animal (32) as well as in human heart (33).
Tissue effect of cortisol could also include potentiation of
cardiac noradrenaline and angiotensin II responsiveness
(34,35) or stimulation of the local renin-angiotensin system
(36). Similar findings were obtained also in different forms
of secondary hypertension; in fact, in our previous work (37)
and in that of Rossi et al. (38) an increase in RWT was
observed in patients with primary aldosteronism, at an early
stage of the disease, when hypervolemia is usually not yet
evident, suggesting a direct action of aldosterone on both
vascular and cardiac growth and remodeling. The lack of
correlation between echo-Doppler parameters of systolic or
diastolic performance and cortisol urinary concentrations
may render less justifiable the findings observed in Cushing
patients. However, it is possible that the long-lasting
exposure to increased cortisol levels, in addition to hormone
circulating amount or BP increase, is the most relevant
determinant of structural and functional characteristics de-
scribed in patients with Cushing’s syndrome.
Some potential limitations of the present study need to be
discussed. First, the impact of BP on cardiac anatomy and
function in Cushing patients may be underestimated be-
cause we have no data on 24-h ambulatory BP values (39),
which may show an altered day-to-night variability in this
disease (40). However, we made an effort by matching
patients with Cushing’s disease not only for BP values and
known duration of hypertension but also for previous
antihypertensive treatment type.
Second, we have evaluated only transmitral early and late
diastolic filling velocities and E wave deceleration time, and
data on isovolumic relaxation time (measured at the LV
outflow tract) are lacking (21,28,29). It has been proposed
that this parameter may more precisely indicate the influ-
ence of hypertension (and other cardiovascular risk factors)
on early abnormalities of diastolic function. However, re-
cent data from the Cardiovascular Health Study have clearly
demonstrated that the E/A ratio may have a predictive value
for the occurrence of subsequent cardiovascular events or
heart failure (8–10).
Lastly, in the group of Cushing patients, five patients
(three hypertensives and two normotensives) had diabetes
mellitus, and we cannot exclude a possible influence of
diabetes per se on cardiac structure and function; however,
in all patients diabetes was well controlled at the time of the
study by oral hypoglycemic agents, and mean fasting glucose
levels were similar in Cushing patients and in controls.
In conclusion, the presence of a low midwall systolic
performance as well as of a diastolic dysfunction has been
observed in patients with Cushing’s syndrome. These ab-
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normalities may contribute to the high risk of cardiovascular
events observed in these patients
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